Want to see SE:HUM full AI Analyst Report?
Top Page
Humana AB
(HUM)
Select Model
Select Model
Rating:56Neutral
Price Target:
kr65.00
▲(28.97% Upside)
Action:Reiterated
Date:06/30/26
The score is held back primarily by weakening revenue trends and elevated leverage, which increase sensitivity if growth remains soft. Offsetting factors include solid and improving free cash flow generation and a reasonable valuation (mid-teens P/E with a ~2.13% dividend yield). Technical signals and earnings-call/corporate-event catalysts were not available to materially shift the rating.
Positive Factors
Free cash flow generation
Consistent positive and growing free cash flow provides durable funding for operations, dividends, capex and gradual debt reduction. Over a 2–6 month horizon this supports investment flexibility and cushions margin pressure, improving financial resilience despite leverage.
Negative Factors
Revenue contraction
A meaningful revenue decline reduces scale economics and pressures utilization- and occupancy-dependent margins. Continued top-line weakness can erode pricing leverage, complicate contract renewals and slow cash flow recovery, increasing operational and refinancing risk over several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Free cash flow generation
Consistent positive and growing free cash flow provides durable funding for operations, dividends, capex and gradual debt reduction. Over a 2–6 month horizon this supports investment flexibility and cushions margin pressure, improving financial resilience despite leverage.
Read all positive factors
Humana AB (HUM) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr3.18B
Dividend Yield2.01%
Average Volume (3M)120.62K
Price to Earnings (P/E)16.5
Beta (1Y)0.69
Revenue Growth-4.47%
EPS Growth6.10%
CountrySE
Employees11,127
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)4.04
Shares Outstanding48,039,394
10 Day Avg. Volume123,370
30 Day Avg. Volume120,620
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.81
Price to Sales (P/S)0.25
P/FCF Ratio3.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.69
Revenue Forecast (FY)kr10.20B
Humana AB Business Overview & Revenue Model
Company Description
Humana AB (publ), founded in 2001 and headquartered in Stockholm, Sweden, offers a wide range of individual and family care services across Sweden, Finland, Norway, and Denmark, serving both children and adults. The company's operations are divide...
How the Company Makes Money
Humana AB makes money by delivering contracted care services and receiving reimbursement/fees—primarily funded by public-sector payors—based on the type and volume of care delivered. Key revenue streams typically include: (1) Personal assistance s...
Humana AB Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
46
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.96B | 10.01B | 10.29B | 9.65B | 9.20B | 8.19B |
| Gross Profit | 888.00M | 831.00M | 896.00M | 757.00M | 9.14B | 8.13B |
| EBITDA | 1.05B | 1.11B | 1.05B | 908.00M | 901.00M | 892.00M |
| Net Income | 199.00M | 237.00M | 144.00M | 176.00M | 210.00M | 276.00M |
Balance Sheet | ||||||
| Total Assets | 9.46B | 9.39B | 10.63B | 10.03B | 9.81B | 9.00B |
| Cash, Cash Equivalents and Short-Term Investments | 254.00M | 366.00M | 583.00M | 675.00M | 690.00M | 695.00M |
| Total Debt | 4.39B | 4.40B | 5.15B | 5.41B | 5.40B | 4.92B |
| Total Liabilities | 6.17B | 6.14B | 7.33B | 7.10B | 7.07B | 6.45B |
| Stockholders Equity | 3.16B | 3.12B | 3.16B | 2.89B | 2.74B | 2.55B |
Cash Flow | ||||||
| Free Cash Flow | 660.00M | 666.00M | 570.00M | 451.00M | 442.00M | 582.00M |
| Operating Cash Flow | 721.00M | 770.00M | 869.00M | 621.00M | 633.00M | 689.00M |
| Investing Cash Flow | -90.00M | 172.00M | -532.00M | -151.00M | -246.00M | -260.00M |
| Financing Cash Flow | -1.05B | -1.13B | -434.00M | -457.00M | -424.00M | -521.00M |
Humana AB Technical Analysis
Positive
50.40
Price Trends
49.87
Positive
46.98
Positive
46.00
Positive
Market Momentum
4.19
Negative
80.91
Negative
95.57
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:HUM, the sentiment is Positive. The current price of 50.4 is below the 20-day moving average (MA) of 52.17, above the 50-day MA of 49.87, and above the 200-day MA of 46.00, indicating a bullish trend. The MACD of 4.19 indicates Negative momentum. The RSI at 80.91 is Negative, neither overbought nor oversold. The STOCH value of 95.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:HUM.
Humana AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | kr2.34B | 36.92 | ― | ― | 10.34% | 2.50% | |
68 Neutral | kr11.84B | 18.60 | 12.96% | 1.56% | 15.74% | 15.67% | |
63 Neutral | kr17.71B | 19.68 | ― | 1.47% | -2.19% | 76.78% | |
61 Neutral | kr1.63B | 40.26 | ― | ― | ― | ― | |
56 Neutral | kr3.18B | 16.51 | 7.53% | 2.01% | -4.47% | 6.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | kr727.37M | -3.69 | -35.03% | ― | ― | 46.92% |
* Healthcare Sector Average
SE:HUM
Humana AB
66.20
30.52
85.53%
SE:ATT
Attendo AB
117.50
54.75
87.25%
SE:AMBEA
Ambea AB
156.60
42.10
36.77%
SE:XSPRAY
Xspray Pharma AB
15.34
-30.36
-66.44%
SE:STIL
Stille AB
260.00
31.00
13.54%
SE:CARA
Carasent AB
23.80
-6.75
-22.09%
Humana AB Corporate Events
Humana AB Updates Share Capital After Redemption of Treasury Shares
Jun 30, 2026
Humana AB has completed a reduction of its outstanding share count after the Annual General Meeting approved the redemption of 3,786,664 treasury shares previously repurchased under earlier authorisations.Following this redemption and a related bo...
Humana Board Backs Ambea’s Premium Takeover Bid with Litigation Upside
Jun 29, 2026
Humana’s board has unanimously recommended that shareholders accept Ambea AB’s public takeover offer, which values Humana at SEK 62.30 per share in cash and shares, excluding any contingent value component. The offer represents premium...
Humana Finland Accelerates Organic Growth with SEK 270m Care Expansion Pipeline
Jun 26, 2026
Humana Finland, part of Nordic care group Humana, is sharpening its organic growth strategy by expanding its pipeline of new care units across all service areas, with a strong emphasis on disability services. The company is also upgrading its infr...
Humana Assistans Appeals Rejection of Damages Claim Over IVO Permit Decision
Jun 25, 2026
Humana Assistans AB, a subsidiary of Humana AB, will appeal a District Court ruling that rejected its damages claim against the Swedish state over the supervisory authority IVO’s earlier decision to revoke its permit. The company argues the ...
Humana denied damages over erroneous permit revocation
Jun 17, 2026
The Stockholm District Court has rejected a damages claim brought by Humana Assistans AB against the Swedish state over the Health and Social Care Inspectorate’s erroneous decision to revoke the company’s operating permit. The court fo...
Humana Ties SEK 2.3 Billion Credit Facility to Sustainability Targets
Jun 16, 2026
Humana AB has linked its SEK 2.3 billion revolving credit facility to key sustainability indicators, tying financing terms to customer satisfaction, employee engagement and reductions in Scope 1 and 2 climate emissions. The move embeds quality of ...
Humana Cancels 3.8 Million Treasury Shares While Keeping Share Capital Unchanged
Jun 15, 2026
Humana AB has completed a previously decided reduction of its share capital through the cancellation of 3,786,664 treasury shares, combined with a bonus issue that keeps total share capital unchanged at about SEK 1,279,656. Following registration ...
Humana AGM Approves Dividend, Share Issuance Mandate and Capital Changes
Jun 1, 2026
Humana AB’s Annual General Meeting approved the 2025 financial statements and confirmed a dividend of SEK 1.35 per share, with remaining earnings carried forward. Shareholders also granted discharge from liability to the board and CEO, re-el...
Humana Sells Elderly Care Property to Cut Debt and Refocus Capital
May 22, 2026
Humana AB and Samhällsbyggnadsbolaget i Norden have agreed to sell an elderly care home property in Strängnäs, in which Humana holds a 50 percent stake, to Northern Horizon Capital for a preliminary total purchase price of SEK 237 m...
Humana Announces Leadership Change in Personal Assistance Division
May 12, 2026
Humana has announced a leadership change in its Group executive management as Business Area Manager for Personal Assistance, Hans Dahlgren, will leave the company after four years. He will remain during his notice period while the recruitment of a...
Stockholm Court Sets June Verdict Date in Humana Permit Dispute
Apr 29, 2026
Humana Assistans 20-29 AB, part of Swedish care group Humana, has pursued legal action against the state over what it claims was an incorrect decision by the Health and Social Care Inspectorate to revoke its operating permit in January 2023. The S...
Humana lifts Swedish margins but profits and cash flow weaken in Q1
Apr 24, 2026
Humana reported a modest improvement in profitability in Sweden, with margins rising from 4.3% to 4.6%, supported by the early effects of an efficiency programme. The company also strengthened its position in social and elderly care through the co...
Humana Reschedules 2026 AGM After Technical Error in Meeting Notice
Apr 24, 2026
Humana AB has withdrawn its previously announced notice convening the Annual General Meeting scheduled for May 7, 2026, after discovering a technical error that prevented shareholders from accessing the notice as required under the Swedish Compani...
Humana Calls 2026 AGM, Expands Options for Shareholder Voting
Apr 24, 2026
Humana AB’s board has called its 2026 Annual General Meeting, to be held on June 1 in Stockholm, giving shareholders the opportunity to participate either in person, by proxy or through a structured postal voting system. The company has set ...
Humana AB Sets June 1, 2026 AGM With Expanded Voting Options
Apr 24, 2026
Humana AB has called its annual general meeting for June 1, 2026, in Stockholm, giving shareholders the opportunity to participate either in person, by proxy, or through postal voting in line with its articles of association and Swedish company la...
Humana Sets April 24 Date to Present First-Quarter 2026 Results
Apr 14, 2026
Humana will publish its interim report for the first quarter of 2026 at 08:00 CET on 24 April, followed by a combined telephone conference and webcast at 09:00 CET where CEO and President Nathalie Boulas Nilsson and CFO Christoffer Herou will pres...
Humana sets May 7, 2026 AGM with expanded postal voting options
Mar 31, 2026
Humana AB has called its annual general meeting for May 7, 2026, in Stockholm, setting out how shareholders can participate either in person, by proxy or through postal voting. The notice details registration deadlines, procedures for nominee̴...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.